Find an expert
Our panel of editors are available for interview
Professor Bryony Dean Franklin
Editor-in-Chief of BMJ Quality & Safety
Professor Bryony Dean Franklin is a hospital pharmacist by background, with 30 years’ experience of research into medication safety, medication use in practice and patient safety more generally. She is Co-Editor-in-Chief of BMJ Quality & Safety, Professor of Medication Safety at UCL School of Pharmacy, Executive Lead Pharmacist for Research at Imperial College Healthcare NHS Trust, Director of the NIHR North West London Patient Safety Research Collaboration and theme lead for the NIHR Health Protection Research Unit in Healthcare Associated Infection and Antimicrobial Resistance at Imperial College London. Professor Franklin has published widely on medication safety, the evaluation of various technologies designed to reduce errors, and the patient’s role in patient safety. Her current post combines research, quality improvement, education and training, medical publishing and hospital pharmacy practice.
Professor Gisli Jenkins
Chair of the Editorial Board for BMJ Open Respiratory Research
Professor Gisli Jenkins is an NIHR Research Professor and holds the Margaret Turner-Warwick Chair of Thoracic Medicine at Imperial College London, Head of the Margaret Turner-Warwick Centre for Fibrosing Lung Diseases at the National Heart and Lung Institute. Prof Jenkins’ research focuses on Interstitial Lung Diseases, and Pulmonary Fibrosis in particular. He is the Principal Investigator of a number of longitudinal observational studies including the PROFILE study, the INJUSTIS Study, the UKILD Post COVID ILD study as well as the DEMISTIFI Multi-Morbidity consortium.
Professor Ronald F. van Vollenhoven
Editor-in-Chief of Lupus Science & Medicine
Professor Ronald F. van Vollenhoven is a distinguished rheumatologist and immunologist, known for his significant contributions in the field. He currently holds the position of Chair of the Department of Rheumatology and Clinical Immunology at Amsterdam UMC and directs the Amsterdam Rheumatology Centre. With a background in immunology and extensive training in Internal Medicine and Rheumatology, he has dedicated his career to the development and evaluation of biological and immunomodulatory treatments for rheumatic diseases. Dr. Van Vollenhoven has played a pivotal role in establishing crucial registries, including the Stockholm registry for biological therapies (STURE database), and has been a principal investigator in numerous clinical trials.
Dr Brandy Shillace
Editor-in-Chief of Medical Humanities
Brandy Schillace, PhD, is Senior Research Associate and Public Engagement and Programs Leader for the Dittrick Museum of Medical History. Dr Schillace writes about intersections of medicine, history, and literature. For ten years, she managed the medical anthropology journal, Culture, Medicine and Psychiatry, and edited its first medical humanities special issue. Brandy’s recent books include Death’s Summer Coat (2016), Clockwork Futures (2017) and Mr Humble and Dr Butcher: A Monkey’s Head, the Pope’s Neuroscientist, and the Quest to Transplant the Soul (2021).
Professor Stephen Kaye
Editor-in-Chief BMJ Open Ophthalmology
Professor of Ophthalmology, Institute of Life Course and Medical Sciences, University of Liverpool where he leads the research into infections of the eye, Consultant Ophthalmologist Royal Liverpool University Hospital where he leads the Cornea and Ocular Surface Disease Service, Vice President of The Royal College of Ophthalmologists, Director of The Liverpool Research Eye Biobank, NHS England National lead for Corneal Transplantation, Honorary Professorship, Queens University, Belfast.
Professor Ganesan Karthikeyan
Editor-in-Chief Open Heart
Professor Karthikeyan is a clinical, interventional cardiologist and a Senior International Fellow of the Population Health Research Institute at McMaster University in Canada, as well as Professor of Cardiology at AIIMS. His research is mainly focused on cardiovascular diseases affecting low and middle income countries, including valvular heart disease, particularly rheumatic heart disease (RHD), mechanical valve thrombosis, anticoagulation, and indigenous drug-eluting stents.